ASTRAZENECA PLC
AstraZeneca is a pharmaceutical company that develops and markets medicines and vaccines for patients with conditions including cancer, cardiovascular and kidney disease, respiratory and immune disorders, and rare diseases. Its business areas include Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Disease. Marketed brands include Imfinzi, Tagrisso, Farxiga/Forxiga, Fasenra, Tezspire, Beyfortus, Soliris and Ultomiris. AstraZeneca makes money from product sales and also records alliance and collaboration revenue for some products. Its registered office is in Cambridge, United Kingdom.
No SEC Form 4 filings for $AZN in the last 30 days.
See all $AZN insider activity →AstraZeneca invested $2 billion in Summit Therapeutics. Summit's ivonescimab, a bispecific antibody, showed statistically significant overall survival benefits in Phase III studies for advanced NSCLC and biliary tract cancer. The company is conducting multiple clinical trials for various cancer indications. The FDA is reviewing ivonescimab for a potential approval in NSCLC.
Rhythm Pharmaceuticals' stock rose 28% after The Wall Street Journal reported AstraZeneca offered to acquire it for $10 billion, or $124 per share. Rhythm closed at $110.68, valuing it at $7.7 billion. AstraZeneca aims to expand its rare disease treatments portfolio. Rhythm focuses on therapies for rare metabolic disorders.
Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.
Over the past 7 days, AlphAI's AI scored 112 news stories mentioning AZN (ASTRAZENECA PLC). Coverage has skewed bullish: 85 bullish, 22 neutral, and 5 bearish.
Recent AZN coverage spans earnings, financial news and regulation.
The sizable cash deployment may weigh on AstraZeneca's near‑term share price while positioning it for future revenue from ivonescimab.
AstraZeneca may face modest downside as investors assess deal financing and integration risk.
Earnings beat plus cost‑saving plan fuels bullish sentiment.
Regulatory acceptance increases probability of eventual label expansion, but no approval yet, keeping near-term upside capped by pending decisions and label conditions.
The partnership may enhance AstraZeneca's preclinical safety assessments but is unlikely to move the stock significantly in the short term.
AlphAI scores every news story that mentions AZN with an AI model for sentiment and relevance, and aggregates insider trades from ASTRAZENECA PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
AstraZeneca invested $2 billion in Summit Therapeutics. Summit's ivonescimab, a bispecific antibody, showed statistically significant overall survival benefits in Phase III studies for advanced NSCLC and biliary tract cancer. The company is conducting multiple clinical trials for various cancer indications. The FDA is reviewing ivonescimab for a potential approval in NSCLC.
Rhythm Pharmaceuticals' stock rose 28% after The Wall Street Journal reported AstraZeneca offered to acquire it for $10 billion, or $124 per share. Rhythm closed at $110.68, valuing it at $7.7 billion. AstraZeneca aims to expand its rare disease treatments portfolio. Rhythm focuses on therapies for rare metabolic disorders.
Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.
AstraZeneca's regulatory filings for a TAGRISSO and ORPATHYS combination for non-small cell lung cancer have been accepted in Europe and Japan. The submissions are supported by Phase III data, but approval is not yet guaranteed. The company expects regulatory decisions to determine the next steps for the treatment. AstraZeneca aims for mid-to-high single-digit revenue growth and low-double-digit core EPS growth in 2026.
AstraZeneca (AZN) and Tremont AI are collaborating to develop AI solutions for preclinical toxicologic pathology, aiming to improve drug safety assessments. Tremont's TRACE model, trained on 15 million image patches, helps identify rare tissue abnormalities. The partnership leverages Tremont's computational pathology expertise and AstraZeneca's drug development needs, with a goal of making safety data interpretation faster and more consistent.
AstraZeneca aims for $1.5B in annual savings by 2029, with $2B in restructuring costs, while Q3 revenue hit $16.2B. Ayrmid bids for Karyopharm's cancer business amid bankruptcy. Sanofi pays Novavax $125M for flu-COVID vaccine trial. uniQure's Huntington's gene therapy gets FDA priority review. Tiziana reports mixed Phase 2a results for nasal MS drug.
ETFs focused on global pharmaceutical companies, particularly those in obesity treatment, saw strong returns amid tech and semiconductor stock declines. Eli Lilly reported Q3 revenue of $24.4B, up 38.6% YoY, driven by obesity drugs Mounjaro and Zepbound. Novo Nordisk and other Big Pharma stocks also rose, benefiting from defensive characteristics and upcoming clinical trial announcements.
The Delhi High Court has temporarily halted the National Pharmaceutical Pricing Authority (NPPA) from taking action against AstraZeneca Pharma India in a drug pricing case, allowing the company to argue that its Symbicort Turbuhaler inhaler may not be subject to price controls. The NPPA alleges overcharging between 2016 and 2025, while AstraZeneca disputes the claims, citing differences in dosage.
AstraZeneca's breast cancer drug Etcamah is priced at $24,392 monthly, slightly above other oral SERDs approved by the FDA, according to the company.
AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.
